Recomodulin (recombinant thrombomodulin alfa) / Asahi Kasei - LARVOL DELTA

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - P1 | N=77 | Terminated | Sponsor: Veloxis Pharmaceuticals | Recruiting ➔ Terminated; Business Decision

Metastases • Trial termination • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pain • Solid Tumor

Synthesis of azelaic acid copolyester plasticizers and their application in PVC. (PubMed, RSC Adv) - "Specifically, the copolyester containing 45% MPO, PHMAZ-45, demonstrated the best plasticizing effect on PVC, with the glass transition temperature of the plasticized PVC system around -35 °C, elongation at break at 908.4%, and a plasticizing efficiency of 254.5%. Additionally, this new type of copolyester plasticizer uses bio-based raw materials, exhibits excellent plasticizing effects, and the preparation process is stable and controllable. It holds promising potential to replace traditional volatile and toxic phthalate esters, presenting significant industrial application value."

Journal

Thiorhodovibrio frisius and Trv. litoralis spp. nov., Two Novel Members from a Clade of Fastidious Purple Sulfur Bacteria That Exhibit Unique Red-Shifted Light-Harvesting Capabilities. (PubMed, Microorganisms) - "The photosynthetic properties of strain 970 were unlike other Thiorhodovibrio spp., which contained typical LH absorbing characteristics of 800-870 nm, as well as a newly discovered absorption band at 908 nm...nov., and the unique strain 970 (=DSM 111777) as Thiorhodovibrio frisius sp. nov."

Journal

Coagulofibrinolytic effects of recombinant soluble thrombomodulin in prolonged porcine cardiac arrest. (PubMed, Resusc Plus) - "A porcine model of prolonged CA/CPR reproduces many of the coagulofibrinolytic abnormalities observed in human cardiac arrest patients. ART-123 demonstrates a combination of anticoagulant and profibrinolytic effects, depending on the timing of its administration relative to cardiac arrest."

Journal • Preclinical • Cardiovascular • Hematological Disorders

Hybrid Ligand Polymerization for Weakly Confined Lead Halide Perovskite Quantum Dots. (PubMed, ACS Appl Mater Interfaces) - "Both thiol ligands promote crystal growth of PQDs, inhibit nonradiative recombination, and cause blue-shifted PL, while the silane moiety of MPTMS manipulates surface chemistry and outperforms owing to its unique cross-linking chemistry characterized by FTIR vibrations at 908 and 1641 cm. Emergence of the diagnostic vibrations is ascribed to hybrid ligand polymerization arising from the silyl tail group that confers the advantages of narrower size dispersion, lower shell thickness, more static surface binding, and higher moisture resistance. In contrast, the superior electrical property of the thiol-passivated PQDs is mostly determined by the covalent S-Pb bonding on the interface."

Journal

The impact of COVID-19 on primary health care services in Qatar: 2 years of response and coping 2020-2021. (PubMed, J Family Med Prim Care) - "However, the newly introduced virtual consultation services in 2020 reached their highest utilization figures in 2021 at 908,965 virtual visits...Nevertheless, PHCC managed to provide alternative virtual services and played a vital role in responding to the pandemic by leading the COVID-19 vaccination campaign in Qatar. However, future research is needed to establish which vulnerable patient groups were most affected by the pandemic, to continue to inform strategies and policies directed at mitigating the impact of future potential pandemics."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology

Scalable Continuous Manufacturing Process of Stereocomplex PLA by Twin-Screw Extrusion. (PubMed, Polymers (Basel)) - "ATR-FTIR depicts the formation of stereocomplex crystallites based on the absorption band at 908 cm (β helix)...A significant improvement in the tensile behavior was observed in comparison to the homopolymers, resulting in a polymer of high strength and toughness. These results lead us to propose stereocomplex PLA as a potential additive/fiber that can reinforce the material properties of neat PLA."

Journal

Asahi Kasei Pharma (BIO 2022) - "medical device). We also look for out-licensing opportunities of Recomodulin for CIPN and AK-1320 for spinal fusion."

Immunology • Musculoskeletal Diseases • Transplantation

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Veloxis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pain • Solid Tumor

Asses Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Veloxis Pharmaceuticals

New P1 trial • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pain • Solid Tumor

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo (clinicaltrials.gov) - P2b | N=0 | Withdrawn | Sponsor: Veloxis Pharmaceuticals | N=300 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Colorectal Adenocarcinoma • Pain

[VIRTUAL] Recombinant Soluble Thrombomodulin in Prolonged Porcine Cardiac Arrest (AHA 2021) - "Our porcine CA model provides an excellent platform for evaluating antithrombotic interventions. Plasma testing after prolonged CA/CPR suggests consumptive coagulopathy, although TEG indicates a persistent hypercoagulable state. ART-123 given before no-flow or just after CPR demonstrates antithrombotic effects, although the specific modes of action depending on the timing of administration."

Preclinical • Cardiovascular • Hematological Disorders • Thrombosis

[VIRTUAL] Asahi Kasei Pharma Corporation (BIO 2021) - "AKP has successfully partnered with large and small organizations to develop and commercialize a variety of innovative treatments including Famvir, Flivas, Toledomin, Xiaflex, Reclast and Kevzara as well as our own original products such as Teribone and Recomodulin. AKP is currently pursuing attractive new in-licensing and research collaboration opportunities in the following therapeutic areas. Area of Interests: Pain management, Musculoskeletal disorders, Autoimmune diseases, Critical care medicine, and Rare diseases."

Critical care • Immunology • Musculoskeletal Diseases • Pain • Rare Diseases

Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET. (PubMed, Ann Intensive Care) - "Results from this exploratory analysis suggest that patients with sustained SAC not receiving concomitant heparin may benefit from ART-123, a fact that should be confirmed in future studies with more restrictive inclusion criteria."

Clinical • Journal • Retrospective data • Hematological Disorders • Infectious Disease • Septic Shock

The Lectin-Like Domain of Thrombomodulin Inhibits β1 Integrin-Dependent Binding of Human Breast Cancer-Derived Cell Lines to Fibronectin. (PubMed, Biomedicines) - "Furthermore, TMD123-Fc and TMD12-Fc inhibited the binding of activated integrins to fibronectin under shear stress in the presence of Ca and Mg but not under strong integrin-activation conditions in the presence of Mg without Ca. This suggests that thrombomodulin Fc fusion protein administered exogenously at a relatively early stage of inflammation may be applied to the development of new therapies that inhibit the binding of β1 integrin of breast cancer cell lines to fibronectin."

Journal • Preclinical • Breast Cancer • Immunology • Inflammation • Oncology • Solid Tumor • FN1

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo (clinicaltrials.gov) - P2b; N=300; Not yet recruiting; Sponsor: Asahi Kasei Pharma America Corporation; Initiation date: Nov 2020 ➔ Jul 2021

Clinical • Trial initiation date • Colorectal Adenocarcinoma • Colorectal Cancer • Pain

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. (PubMed, Cancer Chemother Pharmacol) - P2 | "ART-123 showed a potential preventive effect against OIPN with good tolerability. A larger study with 1-day ART is warranted. NCT02792842, registration date: June 8, 2016."

Clinical • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Pain • Solid Tumor

[VIRTUAL] Hospital Multimodality Care as a Quality Measure for Gastric Cancer (SSO 2020) - " National cohort study of 4,412 patients with resected, locally advanced gastric cancer (i.e.: cT2 or greater and/or cN+) treated at 908 hospitals within the National Cancer Data Base (2006-2015)... Only a quarter of hospitals nationally perform well in delivering MMT. Notably, care at high performing hospitals on individual measures is not associated with improved outcome. Therefore, efforts to improve gastric cancer care should focus on measures that capture the overall quality of MMT."

Clinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo (clinicaltrials.gov) - P2b; N=300; Not yet recruiting; Sponsor: Asahi Kasei Pharma America Corporation

Clinical • New P2b trial • Colorectal Adenocarcinoma • Colorectal Cancer • Pain

Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study. (PubMed, Ann Intensive Care) - "The main effect of the administration of ART-123 may be beneficial for survival outcome in patients with sepsis. In addition, a significant beneficial effect modification on survival outcome was observed between the administration of ART-123 and PMX-HP treatment."

Journal • Infectious Disease • Septic Shock

Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. (PubMed, J Thromb Haemost) - "In patients with sepsis, SAC is associated with higher 28-day mortality. The administration of rhsTM reduced 28-day mortality in patients with SAC, but not in those without SAC."

Journal • Retrospective data • Review

Thrombomodulin alfa not recommended for idiopathic pulmonary fibrosis (Pulmonology Advisor) - P3, N=74; NCT02739165; Sponsor: Asahi Kasei Pharma Corporation; "Use of thrombomodulin alfa...for the treatment of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is not recommended, according to phase 3 clinical trial results....'In conclusion, ART-123 did not improve the 90-day survival proportion in patients with AE-IPF,' the authors wrote."

P3 data

Plasma from Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin (ART-123). (PubMed, Liver Transpl) - "This study suggests that ART-123 is unlikely to provoke bleeding in patients undergoing liver transplantation as proposed clinical dosages have a virtually absent anticoagulant effect in these patients. Clinical studies are required to confirm safety of ART-123 and efficacy on alleviating I/R injury during liver transplantation."

Clinical • Journal

Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes. (PubMed, Crit Care) - No abstract available

Clinical • Journal

Anti-adhesive effects of human soluble thrombomodulin and its domains. (PubMed, Biochem Biophys Res Commun) - "Moreover, since TMD1 might bind to leukocytes via other adhesion receptors than integrins, TMD1 and TMD3 appear to inhibit leukocyte binding to TM on VECs via different mechanisms. In summary, TMD123 (rhsTM), TMD1 or TMD3 is a promising treatment option for sepsis that attenuates integrin-dependent binding of leukocytes to VECs, and may inhibit the undesirable adhesion and migration of leukocytes to VECs in sepsis."

Journal